Omada

By Laura Lovett 03:18 pm September 2, 2020
A new study jointly conducted by digital chronic care management tool Omada and Evidation Health found that patients using Omada’s diabetes management program reduced their A1c level and average of 0.8 over the course of the clinical research.  The study included a total of 195 participants with Type 2 diabetes who had an average baseline A1c of 8.93%. Researchers reported that those participants...
By Dave Muoio 03:57 pm May 19, 2020
Digital chronic-disease-program company Omada Health is leaping into musculoskeletal care thanks to its acquisition of Physera, an app-based platform that includes remote consultations with physical therapists. Although the deal was announced today, Omada said it will "immediately" begin offering the MSK program to its employer, health plan and individual customers. “Integrating a digital...
By Dave Muoio 04:26 pm February 14, 2020
A sample of low-income patients engaged with Omada Health’s digital diabetes prevention program (DPP), achieved weight loss but no major difference in HbA1c levels after a year of use, according to study data recently highlighted by the company. The results — published late last year in the CDC’s Preventing Chronic Disease journal and first previewed at a 2018 public health conference — suggest...
By Laura Lovett 12:22 pm November 14, 2019
Digital chronic care platform Omada is deepening its relationship with Blue Cross and Blue Shield of Minnesota (Blue Cross), inking a new deal that provides the insurer’s commercial plan members access to the startup’s Type 2 diabetes care platform. As part of yesterday’s news, Blue Cross also announced it would be making a strategic investment in Omada; however, the actual value of this...
By Dave Muoio 02:57 pm October 11, 2019
It’s little secret that chronic conditions are a heavy burden on the healthcare system. Diabetes, heart disease, obesity and others can stick with a patient for decades, often leading to increased spending on disease management programs and costly visits when those efforts aren’t making an impact. What’s worse, many of the clinical advances of the past decade or so haven’t substantially moved the...
By Dave Muoio 03:50 pm October 10, 2019
Digital chronic disease management company Omada Health has added onto June’s $73 million funding round with a new strategic investment from Intermountain Ventures. The terms of the deal were not disclosed. WHAT THEY DO Omada pitches its digital coaching programs as a scalable and convenient approach to chronic disease management. The company’s products address hypertension, Type 2 diabetes,...

Omada CEO Sean Duffy. Photo credit: Omada

By Laura Lovett 03:57 pm July 11, 2019
Omada Health, the digital health company that recently raised $73 million, came on to the digital health scene in 2011 with a focus on diabetes and chronic conditions. As the company continues to carve out its legacy in the digital health world, it is taking a cue from a more established industry. “We’re one of the most life sciences-like digital health companies. We don’t fit perfectly into any...
By Dave Muoio 02:22 pm June 26, 2019
San Francisco-based digital chronic disease management company Omada Health has closed a $73 million funding round led by Wellington Management Company. Cigna Ventures, Andreessen Horowitz, U.S. Venture Partners, Norwest Venture Partners, Kaiser Permanente Ventures, Sanofi Ventures, Civilization Ventures and Providence Ventures also contributed. WHAT THEY DO Omada offers a slew of digital...
By Jonah Comstock 09:01 am March 12, 2019
San Francisco-based digital chronic disease managment company Omada Health announced today that it will add fully integrated, cellular-connected glucometers and blood pressure cuffs to its offerings for Type 2 diabetes and hypertension, respectively. The devices are FDA-cleared and can be mailed to program members. The glucometer will come with as many free test strips as users need, the company...
By Dave Muoio 04:19 pm November 14, 2018
De Novo clearance for urinary incontinence wearable. The FDA has granted De Novo clearance to Atlantic Therapeutics’ Innovo therapy device, an externally worn electrical muscle stimulator for the treatment of stress urinary incontinence. The wearable is intended for adult women as a front-line or second-line therapy, and in a multi-center randomized controlled trial recorded an 87 percent rate of...